



Xintela Board recommends Maarten de Château as new Board member

Lund, Sweden, 3 December 2020 –Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings.

Maarten de Château is currently CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the Board of Atrogi, and on the Boards of OxThera, Amarna Therapeutics, Beactica and Cavis Technologies. Maarten was co-founder and CEO of Cormorant Pharmaceuticals – a company that developed a therapeutic antibody in immuno-oncology and that was acquired by Bristol-Myers Squibb in 2016. Prior to that, Maarten held the position of Medical Director at Swedish Orphan Biovitrum; he has also worked in clinical development at Sanofi and as a financial analyst for five years. Maarten holds a MD and PhD from the University of Lund, Sweden.

“I am delighted that Maarten de Château has agreed to join our Board. He will contribute strongly especially to our oncology business and his experience in partnering with big pharma and in finance will be of great value to Xintela. I am excited to work with our new and strengthened board as we progress into clinical studies and commercialization,” says Xintela's Chairman of the Board Gregory Batcheller.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.